Molecular requirements for safer generation of thrombolytics by bioengineering the tissue-type plasminogen activator A chain


  • J. Parcq,

    1. Inserm, Inserm UMR-S U919, University of Caen Basse-Normandie, Serine Proteases and Pathophysiology of the Neurovascular Unit (SP2U), GIP Cyceron, Caen, France
    Search for more papers by this author
  • T. Bertrand,

    1. Inserm, Inserm UMR-S U919, University of Caen Basse-Normandie, Serine Proteases and Pathophysiology of the Neurovascular Unit (SP2U), GIP Cyceron, Caen, France
    Search for more papers by this author
  • A. F. Baron,

    1. Inserm, Inserm UMR-S U919, University of Caen Basse-Normandie, Serine Proteases and Pathophysiology of the Neurovascular Unit (SP2U), GIP Cyceron, Caen, France
    Search for more papers by this author
  • Y. Hommet,

    1. Inserm, Inserm UMR-S U919, University of Caen Basse-Normandie, Serine Proteases and Pathophysiology of the Neurovascular Unit (SP2U), GIP Cyceron, Caen, France
    Search for more papers by this author
  • E. Anglès-Cano,

    1. Inserm, Inserm UMR-S U919, University of Caen Basse-Normandie, Serine Proteases and Pathophysiology of the Neurovascular Unit (SP2U), GIP Cyceron, Caen, France
    Search for more papers by this author
  • D. Vivien

    Corresponding author
    • Inserm, Inserm UMR-S U919, University of Caen Basse-Normandie, Serine Proteases and Pathophysiology of the Neurovascular Unit (SP2U), GIP Cyceron, Caen, France
    Search for more papers by this author

Correspondence: Denis Vivien, Inserm, Inserm UMR-S U919, Université Caen Basse-Normandie, GIP Cyceron, Bd H. Becquerel, BP 5229, Caen, F-14074 France.

Tel.: +33 2 31 47 01 66; fax: +33 2 31 47 02 22.




Thrombolysis with tissue-type plasminogen activator (t-PA) is the only treatment approved for acute ischemic stroke. Although t-PA is an efficient clot lysis enzyme, it also causes damage to the neurovascular unit, including hemorrhagic transformations and neurotoxicity.


On the basis of the mechanism of action of t-PA on neurotoxicity, we aimed at studying the molecular requirements to generate safer thrombolytics.


We produced original t-PA-related mutants, including a non-cleavable single-chain form with restored zymogenicity (sc*-t-PA) and a t-PA modified in the kringle 2 lysine-binding site (K2*-t-PA). Both sc*-t-PA and K2*-t-PA showed fibrinolytic activities similar to that of wild-type t-PA on both euglobulin-containing and plasma-containing clots. In contrast to wild-type t-PA, the two mutants did not promote N-methyl-d-aspartate receptor-mediated neurotoxicity.


We designed t-PA mutants with molecular properties that, in contrast to t-PA, do not induce neurotoxicity.


Tissue-type plasminogen activator (t-PA) is a serine protease of the neurovascular unit released by endothelial cells [1], neurons [2], and glial cells [3]. t-PA is an unusually active zymogen, with full intrinsic activity and low zymogenicity [4]. t-PA promotes fibrinolysis via the conversion of the inactive fibrin-bound zymogen plasminogen into plasmin. In the brain, t-PA shows critical functions and dysfunctions through either plasminogen-dependent or plasminogen-independent mechanisms [5]. Intravenous t-PA can also cross the disrupted blood–brain barrier [6], and thus can induce a neurotoxic effect [5-7].

Since the approval of recombinant t-PA (alteplase, Boehringer-Ingelheim, Paris, France) for the acute treatment of ischemic stroke, experimental data have favored the idea that, beyond its beneficial vascular effects, t-PA may have damaging properties in the cerebral parenchyma [7]. Indeed, t-PA promotes hemorrhagic transformations [8-11]. Moreover, in the brain parenchyma, its interaction with the N-methyl-d-aspartate receptor (NMDAR) in neurons activates signaling processes that result in neuronal death [8]. Such an interaction of t-PA with the N-terminal domain of GluN1 and subsequent neuronal death is reported to be dependent on its kringle 2 domain [12].

Current experimental strategies to improve safer thrombolysis include the use of a plasminogen activator inhibitor-1-derived hexapeptide to inactivate the pro-neurotoxicity of t-PA [13], and a soluble annexin A2 to improve the efficacy of t-PA-induced fibrinolysis [14]. Desmodus rotundus plasminogen activator (DSPA), a serine protease secreted by the D. rotundus salivary glands, shares 66% identity with human t-PA, but lacks a kringle domain as compared with t-PA. DSPA [15] was developed as a third-generation thrombolytic devoid of the above mentioned side-effects of t-PA. Indeed, a number of studies have emphasized the absence of excitotoxicity of this exclusively single-chain serine protease [16-18]. Nonetheless, although DSPA was proposed as a safer thrombolytic for stroke, the last phase III clinical trial (DIAS-2) was unsuccessful [19]. Concerns about the conclusions of the trial could be raised, as the patient inclusion criteria may have been heterogeneous in this study.

On the basis of the foregoing, we generated and characterized two new mutants of t-PA. These mutants include point mutations that yield, for one mutant, a non-cleavable single-chain form of t-PA (sc*-t-PA), and for the second one, a form modified in the kringle 2 lysine-binding site (LBS) that is unable to interact with NMDARs (K2*-t-PA).

Materials and methods

Amino acids are numbered from the N-terminal serine of the mature Rattus norvegicus t-PA sequence (UniProtKB: P19637).


N-methyl-d-aspartate (NMDA) was from Tocris (Bristol, UK); Spectrofluor 444FL and Spectrozyme were from American Diagnostica (ADF Biomedical, Neuville-sur-oise, France); and 6-aminocaproic acid (ε-ACA), Dulbecco's modified Eagle's medium (DMEM), poly(d-lysine), cytosine β-d-arabinoside, extravidin and hygromycin B were from Sigma-Aldrich (L'Isle d'Abeau, France). The QuickChange XL kit was from Stratagene (La Jolla, CA, USA). Plasminogen was from Calbiochem (Nottingham, UK). Lipofectamine 2000, fetal bovine and horse sera and laminin were from Invitrogen (Cergy Pontoise, France). t-PA (alteplase) was from Boehringer-Ingleheim (Paris, France).

Construction of wild-type t-PA (wt-t-PA) and ΔK2-t-PA mutants in the pcDNA5/FRT vector

The rat t-PA cDNA sequence was amplified by PCR with the following primers: 5′-CCGGGATCCTCCTACAGAGCGACC-3′ and 5′-GGCAAGCTTTTGCTTCATGTTGTCTTGAATCCAGTT-3′ (with a His6 tag at the N-terminal position). PCR products were inserted into a pcDNA5/FRT vector (Invitrogen). Fusion PCR was performed to obtain ΔK2-t-PA from wt-t-PA, by use of the same protocol, with the following primers: 5′-CAGGCCGCACGTGGAGTCCTGAGTTGGTCCCTTAGG-3′ and 5′-TCCACCTGCGGCCTG-3′. Final constructs were automatically sequenced.

Site-directed mutagenesis

Mutagenesis of wt-t-PA (t-PA W254R) was performed with the QuikChange XL Kit and the following primers: 5′-GGACCGAAAGCTGACACGGGAATATTGCGACATGTCC-3′ and 5′-GGACATGTCGCAATATTCCCGTGGTCAGCTTTCGGTCC-3′. Non-cleavable t-PA (t-PA R276S) was obtained with the following primers: 5′-TACAAACAGCCTCTGTTTCGAATTAAAGGAGGA-3′ and 5′-TCCTCCTTTAATTCGAAACAGAGGCTGTTTGTA-3′ primers. Mutations were confirmed by sequence analysis.

Human embryonic kidney (HEK)-293 cell cultures and stable transfection

Stable HEK-293 cells transfected with the pFRT/lacZeo vector (HEK-FlpIn; Invitrogen) were grown in RPMI-1640 medium supplemented with 10% fetal bovine serum and 2 mm glutamine. Cells were transfected with Lipofectamine 2000. Positive clones were isolated by hygromycin B selection. The quality of the transfection was assessed by quantitative RT-PCR.

Bioreactor production of the t-PA-related mutants

To produce high yields of mutants, stable transfected HEK-293 cells were grown in a laboratory-scale bioreactor (CELLine AD 1000; Dominique Dutscher SAS, Brumath, France).

Purification of His6 mutants

Purification was performed with a nickel–nitrilotriacetic acid metal-affinity chromatography matrix (Qiagen, Courtaboeuf, France). t-PA variants were then conditioned in an NH4HCO3 0.5 m buffer and stored.

t-PA immunoblotting

Immunoblotting was performed with a mouse mAb raised against a penta-histidine sequence (1 : 1000), and incubation with the appropriate biotinylated-conjugated secondary antibody. The signal was amplified as necessary with extravidin biotin–peroxidase conjugate. Immunoblots were revealed with an enhanced chemoluminescence ECL Plus immunoblotting detection system (Perkin Elmer-NEN, Paris, France).

SDS-PAGE plasminogen–casein zymography

A zymography assay was performed by addition of plasminogen (4.5 μg/mL) and casein (1%) in 10% SDS–polyacrylamide gels. Electrophoresis was performed at 4 °C. Gels were washed with Triton X-100 (2.5%) and incubated for 2 h at 37 °C. Caseinolytic bands were visualized after Coomassie staining.

Amidolytic activity assay

t-PA variants were incubated in the presence of a fluorogenic substrate (5 μm) (Spectrofluor FL444). The reaction was carried out at 37 °C in 50 mm Tris (pH 8.0) containing 150 mm NaCl in a total volume of 100 μL. The amidolytic activity was measured as the change in fluorescence emission at 440 nm (excitation at 360 nm). With Spectrozyme, an amidolytic substrate (Spectrozyme t-PA [Spt-PA]), wt-t-PA and sc*-t-PA (0.3 nm) were incubated with increasing concentrations of Spt-PA (0–1 mm, 12 doses) in a microplate (200 μL per well), and OD405 nm was recorded every minute with a microplate spectrophotometer (ELx 808; BioTek, Colmar, France). Then, the maximal velocity (Vmax) of the reaction was calculated, and the data were plotted as follows:

display math

Fibrin agarose zymography

Proteins (10 μg) and reference proteins (10 μL of t-PA 6 IU mL–1, urokinase plasminogen activator [u-PA] 2.5 IU mL–1, and plasmin 200 nm) were electrophoresed in a 8% polyacrylamide gel under non-denaturing conditions. SDS was then exchanged with 2.5% Triton X-100 before the gel was carefully overlaid on a 1% agarose gel containing 1 mg mL–1 bovine fibrinogen, 100 nm plasminogen, and 0.2 NIH unit mL–1 bovine thrombin. Zymograms were allowed to develop at 37 °C for 12 h. Active proteins in cell lysates were identified by reference to the migration of known markers (u-PA, t-PA, and plasmin).

Clot lysis time

Human plasma was obtained from citrated blood, and the euglobulin fractions, containing β-globulins and γ-globulins, were separated by isoelectric precipitation. The euglobulin solution (100 μL), or the plasma, was supplemented with 15 mm calcium chloride and each of the t-PA mutants at 25, 30, 35 and 40 IU, or 900, 1000, 1100 and 1200 IU, respectively. The time to clot lysis was recorded by OD measurements at 405 nm and 37 °C by reference to the International Reference Preparation (IRP 98/714). Tests were performed in duplicate (from three independent experiments). Results are expressed as the time needed to obtain 50% clot lysis.

Neuronal cell culture

Neuronal cultures were prepared from fetal mice cortices (embryonic day 15–16), as previously described [8]. Various treatments were performed after 14 days in vitro.

Excitotoxic neuronal death

Excitotoxic neuronal death was induced by exposure of cortical neurons to NMDA alone or in the presence of one of the t-PA mutants for 1 h, as previously described [20]. NMDA was incubated at 50 μm final concentration in serum-free DMEM supplemented with 10 μm glycine. t-PA variants were used at 0.3 μm amidolytic activity final concentration (relative to alteplase), unless otherwise mentioned. Neuronal death was quantified 24 h later by measuring the activity of lactate dehydrogenase released from damaged cells into the bathing medium with a cytotoxicity detection kit (Roche Diagnostics, Mannheim, Germany).

Statistical analyses

All statistical analyses were performed with the two-tailed Kruskall–Wallis test, followed by post hoc comparisons with the two-tailed Mann–Whitney test. Results are expressed as mean ± standard deviation. A P-value of < 0.05 was considered to indicate statistical significance.


Generation of new thrombolytics originating from t-PA

Structural differences between human t-PA (UniProtKB: P00750), rat t-PA (UniProtKB: P19637) and bat DSPAα1 (hereafter termed DSPA; UniProtKB: P98119) were studied by the use of multiple alignments. DSPA contains a single kringle domain with a similar amino acid sequence to t-PA's kringle 1 domain (Fig. 1A) and the absence of a constitutive LBS (Fig. 1A, black boxes). t-PA's kringle 2 domain contains a constitutive LBS formed by Asp237, Asp239, and Trp254. Analysis of the primary sequence of DSPA revealed a lack of the cleavage site Arg276–Iso277, which is present in t-PA (Fig. 1B).

Figure 1.

Primary structure of human tissue-type plasminogen activator (t-PA), rat t-PA, and Desmodus rotundus plasminogen activator (DSPA)α1. (A) Sequence analysis of the kringle domain of DSPA reveals naturally occurring amino acid substitutions leading to a non-functional lysine-binding site: the anionic charges at Asp237 and Asp239 (dashed black box 1) and the hydrophobic Trp254 (black box 2) are missing. (B) Although DSPA is an exclusively single-chain serine protease, both human and rat t-PA can be processed into a two-chain form after cleavage at the arginine at position 276 (rat numbering: black box).

We generated three mutants derived from rat t-PA (R. norvegicus wt-t-PA): (i) a rat t-PA genetically engineered with complete deletion of its kringle 2 domain (from Cys181 to Cys262), hereafter termed ΔK2-t-PA; (ii) a rat t-PA containing a tryptophan to arginine point mutation at position 254 (W254R), hereafter termed K2*-t-PA; and (iii) an exclusively single-chain rat t-PA obtained by an arginine to serine point mutation at position 276 (R276S), hereafter termed sc*-t-PA (Table 1). When subjected to SDS-PAGE and immunoblotting, wt-t-PA, sc*-t-PA and K2*-t-PA showed similar molecular masses, whereas ΔK2-t-PA showed a molecular mass reduced by 15 kDa (Fig. 2A). sc*-t-PA was present in its exclusively single-chain form, whereas wt-t-PA, K2*-t-PA and ∆K2-t-PA were present in both their single-chain and two-chain forms (at 35 kDa and 25 kDa for ∆K2-t-PA). As a control, the purified sc*-t-PA was incubated with 5 nm plasmin at 37 °C (for 24 h) prior to SDS-PAGE immunoblotting. Plasmin did not cleave sc*-t-PA as it did wt-t-PA (Fig. 2B). Thus, the R276S point mutation (sc*-t-PA) leads to the generation of a non-cleavable form of t-PA.

Table 1. Biochemical characteristics of the tissue-type plasminogen activator (t-PA) variants: (i) sequence provided in the Supplementary Data; (ii) fibrinolytic activities obtained from euglobulin clot lysis time assay by reference to the International Reference Preparation (IRP 98/714), using the time to obtain 50% clot lysis
NameSequence/mutationTwo-chain formAmidolytic activityApparent fibrinolytic activity (IU mg–2)
  1. DSPA, Desmodus rotundus plasminogen activator.

Human t-PAUniProtKB: P00750YesYes
DSPAαlUniProtKB: P98119NoLimited
Rat wt-t-PAUniProtKB: P19637′1YesYes203 605
Rat scMPAArg276→SerNoLimited184 136
Rat K2MPATryp254→ArgYesYes155 559
Rat AK2-t-PACys181 to Cys262 deletionYesYes319 903
Figure 2.

Biochemical characterization of the tissue-type plasminogen activator (t-PA) variants. (A) Equal amounts (100 ng) of wt-t-PA, sc*-t-PA, K2*-t-PA and ΔK2-t-PA mutants were subjected to immunoblotting. (B) Time-course of plasmin-dependent cleavage (5 nm) of wt-t-PA and sc*-t-PA mutants. Although wt-t-PA was converted by plasmin, sc*-t-PA remained uncleaved. (C, D) Activity of the t-PA-related mutants measured either on a fluorogenic substrate (C) or by plasminogen–casein zymography assays (D); ***P < 0.01. (E, F) Michaelis–Menten plots for wt-t-PA and sc*-t-PA activity with Spectrozyme t-PA (SptPA) and the corresponding Vmax and KM. AU: arbitrary unit; OD: optical density; tc-t-PA: two-chain t-PA.

t-PA is known to bind and cleave several substrates in addition to plasminogen (such as the GluN1 subunit), with no identified allosteric regulator. Therefore, we evaluated the intrinsic proteolytic activity of each of the t-PA variants. For this purpose, amidolytic activity assays with a fluorogenic substrate (Spectrofluor) (Fig. 2C) and plasminogen-containing zymography assays (Fig. 2D) were performed for the different t-PA-related mutants. The data revealed that, although kringle 2-related mutants (ΔK2-t-PA and K2*-t-PA) showed amidolytic activity similar to that observed for wt-t-PA, sc*-t-PA did not. To further investigate the behavior of the sc*-t-PA variants as compared with wt-t-PA, we determined the KM values of these two plasminogen activators by using the amidolytic Spectrozyme as the substrate. The data showed that the point mutation within the cleavage site of t-PA led to a four-fold increase in the KM as compared with wt-t-PA (430 μm and 110 μm, respectively; see Fig. 2E,F). Hereafter, concentrations of the t-PA mutants are normalized to their intrinsic amidolytic activity, unless otherwise mentioned.

Kringle 2-related mutants (ΔK2-t-PA and K2*-t-PA) are fibrinolytic and do not promote NMDAR-mediated neurotoxicity

Kringle 2-related mutants were characterized for their ability to initiate fibrinolysis on fibrin–agarose plates. ΔK2-t-PA and K2*-t-PA activated plasminogen into plasmin in the presence of fibrin, as did wt-t-PA (Fig. 3A). To quantify the fibrinolytic activity of the kringle 2-related mutants, an in vitro clot lysis assay, performed on euglobulin fractions from platelet-poor human plasma clots as the substrate, revealed that ΔK2-t-PA had enhanced fibrinolytic activity as compared with wt-t-PA (+ 57%, n = 3; Fig. 3B). K2*-t-PA showed decreased fibrinolytic activity as compared with wt-t-PA (− 24%, n = 3; Fig. 3B). As α2-antiplasmin may influence t-PA-induced fibrinolysis, the fibrinolytic activity of each of the t-PA mutants generated was tested against clots derived from whole plasma. ΔK2-t-PA showed increased fibrinolytic activity (+ 131%, P < 0.02; Fig. 3C) and K2*-t-PA showed decreased fibrinolytic activity (− 65%, n = 3, P < 0.02; Fig. 3C) as compared with wt-t-PA.

Figure 3.

ΔK2-t-PA and K2*-t-PA are fibrinolytics. (A) ΔK2-t-PA and K2*-t-PA show fibrinolytic activity similar to that of wt-t-PA when subjected to a fibrin-containing zymography assay. (B, C) K2*-t-PA shows lower fibrinolytic activity than wt-t-PA when tested on the euglobulin clot lysis assay (– 24% [B]) and on the plasma clot lysis assay (– 65% [C]). ΔK2-t-PA shows enhanced fibrinolytic activity as compared with wt-t-PA (+ 57% on the euglobulin clot lysis assay [B] and + 131% on the plasma clot lysis assay [C]). Fibrinolytic activities were normalized to that of wt-t-PA; **P < 0.02. t-PA, tissue-type plasminogen activator.

To estimate the effect of kringle-related t-PA mutants on NMDAR-mediated neurotoxicity, pure cultures of cortical neurons were subjected to NMDA exposure either alone or in combination with either purified ΔK2-t-PA or K2*-t-PA (0.3 μm) prior to measurement of neuronal death 24 h later. wt-t-PA caused a 39% potentiation of NMDAR-mediated excitotoxicity (71% of the cells died, as compared with 51% with NMDA alone), an effect similar to what was observed for human t-PA-containing alteplase (Fig. 4A; n = 3, P < 0.01), whereas ΔK2-t-PA and K2*-t-PA (Fig. 4B; n = 4, P < 0.01) showed no potentiation of NMDA-mediated neurotoxicity. Thus, substitution of Trp254, a constitutive amino acid of the LBS of kringle 2 of t-PA, confirms that kringle 2 is critical in mediating the pro-neurotoxicity of t-PA. Accordingly, similar experiments performed in the presence of ε-ACA, a lysine analog that is known to compete with the LBS of t-PA, showed that blockage of LBS function prevented wt-t-PA-induced potentiation of NMDAR-mediated neurotoxicity (Fig. 4C; n = 5, P < 0.01).

Figure 4.

Inactivation of the constitutive lysine-binding site of the tissue-type plasminogen activator (t-PA) kringle 2 domain abolishes t-PA-mediated neurotoxicity. (A–C) Neuronal death was assessed by measuring lactate dehydrogenase release in the bathing medium. (A) Human t-PA or rat wt-t-PA (0.3 μm; three independent experiments). (B) wt-t-PA, ΔK2-t-PA or K2*-t-PA (0.3 μm; four independent experiments). (C) Human t-PA (0.3 μm) in the presence or absence of 0.1 mm of the lysine analog ε-aminocaproic acid (ε-ACA) (five independent experiments). Data are presented as the mean ± standard deviation of neuronal death as percentage relative to control; ***P < 0.01. NMDA, N-methyl-d-aspartate; NS, not significant.

A zymogenic t-PA (sc*-t-PA) is also a fibrinolytic that does not promote NMDAR-mediated neurotoxicity

We tested both the fibrinolytic activity and the neurotoxicity of sc*-t-PA. In contrast to its reduced intrinsic amidolytic activity (Fig. 2C,D), sc*-t-PA remained fibrinolytic in the presence of fibrin (− 10% on the euglobulin clot lysis assays, n = 3 [Fig. 5A,B] and + 27% on the plasma clot lysis assays, n = 3 [Fig. 5C]). This mutant was then tested for its ability to influence NMDAR-mediated neurotoxicity in cortical neurons. sc*-t-PA did not potentiate NMDAR-dependent excitotoxicity as compared with wt-t-PA (n = 3, P < 0.01; Fig. 6).

Figure 5.

Fibrin reveals the ability of sc*-t-PA to activate plasminogen to plasmin. Fibrin reveals sc*-t-PA's ability to activate fibrin-bound plasminogen to plasmin as assessed by plasminogen fibrin–agarose zymography (A), euglobulin clot lysis assay (B) (90% of the activity measured for wt-t-PA, n = 3), and plasma clot lysis assay (C) (+ 27% as compared with wt-t-PA, n = 3). Fibrinolytic activities were normalized to that of wt-t-PA; **P < 0.02. t-PA, tissue-type plasminogen activator.

Figure 6.

Restoring tissue-type plasminogen activator (t-PA) zymogenicity rescues neurons from t-PA potentiation of N-methyl-d-aspartate (NMDA)-mediated neurotoxicity. Neuronal death was assessed from neurons treated with NMDA alone or with either rat wt-t-PA or rat sc*-t-PA (0.3 μm; n = 12, four independent experiments). Data are presented as the mean ± standard deviation of neuronal death as percentage relative to control; ***P < 0.01. NS, not significant.


Although thrombolysis with t-PA is clearly beneficial for stroke patients [21] (NINDS, ECASS, and Epithet), the benefits are limited to a low percentage of patients, owing to a 4.5-h therapeutic window and possible deleterious effects of t-PA. Thus, the development of a new class of thrombolytics with higher fibrinolytic efficiency, a lower risk of hemorrhagic transformations and reduced neurotoxicity is of seminal importance.

Several clues in rodent models indicate that the benefit of t-PA-induced thrombolysis is counterbalanced by side-effects such as neurotoxicity [7]. At the mechanistic level, the t-PA–NMDAR interaction triggers a dramatic increase in NMDAR signaling that leads to increased neuronal death [8, 12, 20, 22]. This mechanism: (i) requires the proteolytic activity of t-PA; (ii) is dependent on the kringle 2 domain of t-PA; and (iii) requires GluN1/GluN2D-containing NMDARs. Furthermore, immunotherapy to prevent the interaction of t-PA with the GluN1 subunit of the NMDAR dramatically reduces ischemic damage and improves neurological scores [23]. Similarly, although intravenous t-PA augments the lesion volume in a rat model of NMDA-induced excitotoxic lesions, DSPA (which lacks the kringle 2 domain) does not [24]. Nevertheless, despite both its increased fibrinolytic activity and its lack of neurotoxicity as compared with t-PA, the last clinical trial performed with DSPA was unsuccessful [19].

The present study indicates that the kringle 2 domain (via the LBS-constitutive tryptophan at position 254) is critically involved in mediating the t-PA-induced potentiation of NMDAR-induced neuronal death. In addition, deletion of t-PA's kringle 2 domain increases its fibrinolytic activity, a finding that was previously reported for DSPA [18]. Thus, as reported for DSPA, lack of the kringle 2 domain or disruption of its LBS is conducive to a lack of neurotoxicity [12].

Moreover, comparative studies of the primary structures of DSPA and t-PA suggest a potential role of the low zymogenicity of t-PA in its damaging effects. We found that, in the absence of fibrin, the non-cleavable single-chain t-PA (sc*-t-PA, R276S) partly restored its amidolytic zymogenicity. Furthermore, inhibition of its intrinsic activity led to the generation of a form of t-PA that lacked neurotoxicity. Interestingly, the fibrinolytic activity of sc*-t-PA is revealed by fibrin clots. These data are in agreement with a study demonstrating that mutation of the cleavage site of sc-t-PA (R276G) lowers its intrinsic amidolytic activity [25].

We generated and characterized a set of original fibrinolytics derived from t-PA: a fibrinolytic K2*-t-PA characterized by a lack of pro-neurotoxicity, and an sc*-t-PA characterized by both 4.4-fold reduced amidolytic activity and lack of pro-neurotoxicity, but with conserved fibrinolytic activity. The apparent fibrinolytic activity measured for each t-PA mutant, with the euglobulin-containing clot lysis assay, confirmed previous data. As previously found for desmoteplase [18, 26], ∆K2-t-PA showed increased fibrinolytic activity (+ 57%) as compared with wt-t-PA. In contrast, a point mutation in its kringle 2 domain (W254R) led to a decrease in its apparent fibrinolytic activity (− 24%). These data are in agreement with reduced stimulation by fibrin, a process that is dependent on the kringle 2 domain [27]. sc*-t-PA showed an apparent activity that was very similar to that of wt-t-PA (− 10%).

t-PA mediates its deleterious effects via an interaction with NMDAR and activation of platelet-derived growth factor (PDGF)-CC to PDGF-C [8, 12, 20, 28], as well as through a mechanism involving its kringle 2 domain. The point mutation W254R in the kringle 2 domain of t-PA may lower its ability to activate PDGF-CC and thus to limit hemorrhagic transformations [9]. These in vitro data provide the basis for further studies to evaluate the efficacy of this new generation of fibrinolytics in experimental models of thrombosis, prior to their possible use in clinical situations.

In conclusion, the present article reports that molecular engineering can produce novel and efficacious molecular variants based on existing therapeutic drugs. We postulate that a combination of the mutations W254R/W253R and R276S/R275S in rat and human sequences, respectively, may provide a relevant and optimized fibrinolytic treatment with future clinical applications.


We are grateful to A. Young and C. Ali for help with the manuscript.

Disclosure of Conflict of Interests

This work was supported by the Institut National de la Santé Et de la Recherche Médicale, the French Ministry of Research and Technology, and the Eurostroke-Arise Program (FP7/2007-2013-201024).